AMD (AMD) Reports In-Line Q2 EPS, Q3 Revenue Guidance Misses Views
Get Alerts AMD Hot Sheet
Price: $551.63 +2.65%
Revenue Growth %: +46.3%
Financial Fact:
Amortization of acquired intangible assets: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +46.3%
Financial Fact:
Amortization of acquired intangible assets: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
AMD (NASDAQ: AMD) reported Q2 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.52 billion.
GUIDANCE:
AMD sees Q3 2019 revenue of $1.8 billion, versus the consensus of $1.95 billion.
- AMD’s outlook statements are based on current expectations. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Cautionary Statement” below.
- For the third quarter of 2019, AMD expects revenue to be approximately $1.8 billion, plus or minus $50 million, an increase of approximately 18 percent sequentially and approximately 9 percent year-over-year. The sequential and year-over-year increases are expected to be driven by Ryzen, EPYC and Radeon product sales. AMD expects non-GAAP gross margin to be approximately 43 percent in the third quarter of 2019.
- For full year 2019, AMD now expects revenue to increase a mid-single digit percent over 2018 driven by significant sales growth of our new Ryzen, EPYC and Radeon processors, partially offset by lower than expected semi-custom revenue. Revenue excluding semi-custom is expected to grow approximately 20 percent year over year. AMD expects non-GAAP gross margin to be approximately 42 percent for 2019.
For earnings history and earnings-related data on AMD (AMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Worried the AI trade has gone too far? Evercore likes these 4 stocks
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share